BMS-JPM-20240108.pdf

1、January 8,2024J.P.Morgan Presentation Highly ConfidentialForward looking statements and non-GAAP financial information 2This presentation(as well as the oral statements made with respect to information contained in this presentation)contains statements about Bristol-Myers Squibb Companys(the“Company

2、”)future financial results,plans,business development strategy,anticipated clinical trials,results and regulatory approvals that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995.All statements that are not sta

3、tements of historical facts are,or may be deemed to be,forward-looking statements.Actual results may differ materially from those expressed in,or implied by,these statements as a result of various factors,including,but not limited to,(i)new laws and regulations,(ii)our ability to obtain,protect and

4、maintain market exclusivity rights and enforce patents and other intellectual property rights,(iii)our ability to achieve expected clinical,regulatory and contractual milestones on expected timelines or at all,(iv)difficulties or delays in the development and commercialization of new products,(v)dif

5、ficulties or delays in our clinical trials and the manufacturing,distribution and sale of our products,(vi)adverse outcomes in legal or regulatory proceedings,(vii)risks relating to acquisitions,divestitures,alliances,joint ventures and other portfolio actions and(viii)political and financial instab

6、ility,including changes in general economic conditions.These and other important factors are discussed in the Companys most recent annual report on Form 10-K and quarterly reports on Form 10-Q and current reports on Form 8-K.These documents are available on the U.S.Securities and Exchange Commission